side effects of glp 1 tirzepatide Effects: What to Expect & How to Manage (2026 Guide) pros and cons of microdosing

NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease

This prevents the gap in therapeutic coverage that would occur from dropping to minimal doses when you have already demonstrated tolerance for higher drug exposure

To this day, several clinical trials are ongoing in a large panel of age-related diseases, but their validation remains uncertain (Table 1)

Botanical ingredient forensics: detection of attempts to deceive commonly used analytical methods for authenticating herbal dietary and food ingredients and supplements

For a 300mcg dose: 300 / 2,500 x 100 = 12 units